Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, provide insight on common signs and symptoms of follicular lymphoma (FL) and factors to consider when selecting first-line therapy.

Tycel Jovelle Phillps, MD, shares second-line treatment approaches for the management of follicular lymphoma and examines the use of PI3K inhibitors.

Dr Alexey Danilov reviews the 2-year follow-up of the phase 2 CHRONOS-1 study evaluating the use of copanlisib monotherapy in relapsed/refractory follicular lymphoma.

Expert hematologist-oncologists examine the use of tazemetostat based on a phase 2 trial for relapsed/refractory follicular lymphoma and consider clinical implications.

Dr Tycel Jovelle Phillips reviews key ongoing trials in relapsed/refractory follicular lymphoma.

Tycel Jovelle Phillips, MD, and Alexey Danilov, MD, share insights on common signs and symptoms of marginal zone lymphoma and approaching initial therapy.

Experts in hematology/oncology discuss second-line and beyond treatment options for patients with MZL and comment on copanlisib monotherapy for the management of R/R MZL as seen in the phase 2 CHRONOS-1 study.

Tycel Jovelle Phillips, MD, discusses recent updates from the CHRONOS-3 trial of copanlisib in R/R MZL and clinical implications of the results of this study.

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, discuss strategies for selecting the appropriate treatment for patients with relapsed/refractory marginal zone lymphoma.

Drs. Alexey Danilov and Tycel Jovelle Phillips share insight on emerging agents and future directions for the management of marginal zone lymphoma.